RRC ID 69788
Author Chueahongthong F, Tima S, Chiampanichayakul S, Berkland C, Anuchapreeda S.
Title Co-Treatments of Edible Curcumin from Turmeric Rhizomes and Chemotherapeutic Drugs on Cytotoxicity and FLT3 Protein Expression in Leukemic Stem Cells.
Journal Molecules
Abstract This study aims to enhance efficacy and reduce toxicity of the combination treatment of a drug and curcumin (Cur) on leukemic stem cell and leukemic cell lines, including KG-1a and KG-1 (FLT3+ LSCs), EoL-1 (FLT3+ LCs), and U937 (FLT3- LCs). The cytotoxicity of co-treatments of doxorubicin (Dox) or idarubicin (Ida) at concentrations of the IC10-IC80 values and each concentration of Cur at the IC20, IC30, IC40, and IC50 values (conditions 1, 2, 3, and 4) was determined by MTT assays. Dox-Cur increased cytotoxicity in leukemic cells. Dox-Cur co-treatment showed additive and synergistic effects in several conditions. The effect of this co-treatment on FLT3 expression in KG-1a, KG-1, and EoL-1 cells was examined by Western blotting. Dox-Cur decreased FLT3 protein levels and total cell numbers in all the cell lines in a dose-dependent manner. In summary, this study exhibits a novel report of Dox-Cur co-treatment in both enhancing cytotoxicity of Dox and inhibiting cell proliferation via FLT3 protein expression in leukemia stem cells and leukemic cells. This is the option of leukemia treatment with reducing side effects of chemotherapeutic drugs to leukemia patients.
Volume 26(19)
Published 2021-9-24
DOI 10.3390/molecules26195785
PII molecules26195785
PMID 34641328
PMC PMC8510311
MeSH Antigens, Neoplasm / drug effects Antigens, Neoplasm / metabolism Cell Cycle Proteins / drug effects Cell Cycle Proteins / metabolism Cell Line, Tumor Cell Proliferation / drug effects Cell Survival / drug effects Curcuma / chemistry Curcumin / pharmacology* Cytoskeletal Proteins / drug effects Cytoskeletal Proteins / metabolism Dose-Response Relationship, Drug Doxorubicin / pharmacology* Drug Synergism Gene Expression Regulation, Neoplastic / drug effects Humans Idarubicin / pharmacology* Leukemia, Myeloid, Acute / drug therapy Leukemia, Myeloid, Acute / metabolism* Rhizome / chemistry fms-Like Tyrosine Kinase 3 / metabolism*
IF 3.267
Human and Animal Cells EoL-1 cell(RCB0641)